# Johnson & Johnson Pharmaceutical trials: 465 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 465 trials with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: 465 rows for $23.25, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/johnson-and-johnson-pharmaceutical-research-and-development-l-l-c

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 465
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 465, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 1, 2020 | NCT04330248 | A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04330248) |
| April 4, 2014 | NCT02103985 | A Study of Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy Participants | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02103985) |
| January 30, 2014 | NCT02049697 | A Study to Evaluate of the Absorption, Metabolism, and Excretion of 14C-JNJ-39823277 in Healthy Male Participants | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02049697) |
| December 30, 2013 | NCT02023255 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39393406 in Healthy Participants | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02023255) |
| December 24, 2013 | NCT02019485 | A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under... | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02019485) |
| November 18, 2013 | NCT01986491 | A Study of Solid Formulations of JNJ-39393406 in Healthy Male Participants | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01986491) |
| November 11, 2013 | NCT01981278 | A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg... | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01981278) |
| September 26, 2013 | NCT01951053 | A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01951053) |
| September 24, 2013 | NCT01949610 | A Study to Evaluate Absorption, Metabolism, and Excretion of 14C-JNJ26489112 in Healthy Male Participants | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy Participants | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01949610) |
| August 30, 2013 | NCT01932333 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01932333) |
| August 30, 2013 | NCT01932320 | A Study to Evaluate the Relative Bioavailability, Food Effect and Effect of Ketoconazole on the Rate and Extent of Absorption of Solid... | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01932320) |
| July 16, 2013 | NCT01900587 | A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the... | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01900587) |
| June 13, 2013 | NCT01877226 | Phase 1 Pharmacokinetic Study of Tapentadol Prolonged-Release 250 Milligram (mg) Formulation in Healthy Participants | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01877226) |
| March 29, 2013 | NCT01821027 | A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in... | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01821027) |
| March 20, 2013 | NCT01814982 | An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain Injury | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | Terminated | Traumatic Brain Injury | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01814982) |
| March 18, 2013 | NCT01812642 | A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | Completed | Schizophrenia | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01812642) |
| February 13, 2013 | NCT01791231 | A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01791231) |
| February 8, 2013 | NCT01787357 | A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01787357) |
| January 3, 2013 | NCT01759576 | A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of... | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Renal Insufficiency, Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01759576) |
| December 25, 2012 | NCT01756417 | A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in... | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01756417) |
| December 25, 2012 | NCT01756404 | Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01756404) |
| December 12, 2012 | NCT01748526 | A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01748526) |
| November 26, 2012 | NCT01733108 | A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy... | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01733108) |
| October 31, 2012 | NCT01718652 | A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01718652) |
| October 25, 2012 | NCT01714206 | A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers. | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01714206) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 138 |
| Phase 2 | 94 |
| Phase 2/3 | 7 |
| Phase 3 | 186 |
| Phase 4 | 20 |
| Not applicable | 1 |
| Observational | 19 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 413 |
| Terminated | 45 |
| Withdrawn | 6 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 73 |
| Anemia | 58 |
| Neoplasms | 30 |
| Mood Disorders | 25 |
| Diabetes Mellitus, Type 2 | 22 |
| Pain | 22 |
| Epilepsy | 21 |
| Bipolar Disorder | 21 |
| Seizures | 19 |
| Psychotic Disorders | 18 |
| Obesity | 17 |
| Alzheimer Disease | 15 |
| Mania | 13 |
| Epilepsies, Partial | 12 |
| Dementia | 12 |
| Migraine Disorders | 11 |
| Brain Diseases | 10 |
| Breast Neoplasms | 8 |
| Osteoarthritis | 8 |
| Arthralgia | 8 |
| Headache | 8 |
| Memory Disorders | 7 |
| Low Back Pain | 7 |
| Hypertension | 7 |
| Diabetes Mellitus | 7 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Mediators in the United States](https://specstream.ai/data/businesses/mediators/united-states)
- [Occupational therapy clinics in the United States](https://specstream.ai/data/businesses/occupational-therapy-clinics/united-states)
- [Personal injury law firms in the United States](https://specstream.ai/data/businesses/personal-injury-law-firms/united-states)
- [Psychology practices in the United States](https://specstream.ai/data/businesses/psychology-practices/united-states)
- [Screen printers in the United States](https://specstream.ai/data/businesses/screen-printers/united-states)
